Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates

被引:122
|
作者
Kuipers, ME
de Vries, HG
Eikelboom, MC
Meijer, DKF
Swart, PJ
机构
[1] Univ Groningen, Inst Drug Studies, Univ Ctr Pharm, Sect Pharmacokinet & Drug Delivery, NL-9713 AV Groningen, Netherlands
[2] Univ Groningen Hosp, Sect Med Microbiol, NL-9713 GZ Groningen, Netherlands
关键词
D O I
10.1128/AAC.43.11.2635
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Because of the rising incidence of failures in the treatment of oropharyngeal candidosis in the case of severely immunosuppressed patients (mostly human immunodeficiency virus [HIV]-infected patients), there is need for the development of new, more effective agents and/or compounds that support the activity of the common antifungal agents. Since lactoferrin is one of the nonspecific host defense factors present in saliva that exhibit antifungal activity, we studied the antifungal effects of human, bovine, and iron-depleted lactoferrin in combination with fluconazole, amphotericin B, and 5-fluorocytosine in vitro against clinical isolates of Candida species. Distinct antifungal activities of lactoferrin were observed against clinical isolates of Candida. The MICs generally were determined to be in the range of 0.5 to 100 mg.ml(-1). Interestingly, in the combination experiments we observed pronounced cooperative activity against the growth of Candida by using lactoferrin and the three antifungals tested. Only in a limited concentration range was minor antagonism detected. The use of lactoferrin and fluconazole appeared to be the most successful combination. Significant reductions in the minimal effective concentrations of fluconazole were found when it was combined with a relatively low lactoferrin concentration (1 mg/ml). Such combinations still resulted in complete growth inhibition, while synergy of up to 50% against several Candida species was observed. It is concluded that the combined use of lactoferrin and antifungals against severe infections with Candida is an attractive therapeutic option. Since fluconazole-resistant Candida species have frequently been reported, especially in HIV infected patients, the addition of lactoferrin to the existing fluconazole therapy could postpone the occurrence of species resistance against fluconazole. Clinical studies to further elucidate the potential utility of this combination therapy have been initiated.
引用
收藏
页码:2635 / 2641
页数:7
相关论文
共 50 条
  • [21] Effect of porphyrin metalation and synergistic combination with fluconazole in antifungal PDT against Candida spp
    Murage, Margaret W.
    Amuhaya, Edith K.
    Mbatia, Betty N.
    Muge, Edward K.
    JOURNAL OF PORPHYRINS AND PHTHALOCYANINES, 2025,
  • [22] In vitro fungistatic effects of a lactoferrin containing mouthwash upon various species of Candida
    Clover, G
    XIV INTERNATIONAL AIDS CONFERENCE: CLINICAL SCIENCES AND CARE, 2002, : 281 - 284
  • [23] Mechanism of Antifungal Action of Monoterpene Isoespintanol against Clinical Isolates of Candida tropicalis
    Contreras Martinez, Orfa Ines
    Angulo Ortiz, Alberto
    Santafe Patino, Gilmar
    MOLECULES, 2022, 27 (18):
  • [24] Antifungal Activity and Mode of Action of Miltefosine Against Clinical Isolates of Candida krusei
    Wu, Yongqin
    Wu, Mengying
    Gao, Jing
    Ying, Chunmei
    FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [25] In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida
    Qiao, Jianjun
    Gao, Peiping
    Jiang, Xiaoling
    Fang, Hong
    ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2013, 12
  • [26] Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp.
    MartinMazuelos, E
    Aller, AI
    Morilla, D
    Montero, O
    CHEMOTHERAPY, 1996, 42 (02) : 112 - 117
  • [27] In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida
    Jianjun Qiao
    Peiping Gao
    Xiaoling Jiang
    Hong Fang
    Annals of Clinical Microbiology and Antimicrobials, 12
  • [28] Synergistic Antifungal Activity of Synthetic Peptides and Antifungal Drugs against Candida albicans and C. parapsilosis Biofilms
    Bezerra, Leandro P.
    Freitas, Cleverson D. T.
    Silva, Ayrles F. B.
    Amaral, Jackson L.
    Neto, Nilton A. S.
    Silva, Rafael G. G.
    Parra, Aura L. C.
    Goldman, Gustavo H.
    Oliveira, Jose T. A.
    Mesquita, Felipe P.
    Souza, Pedro F. N.
    ANTIBIOTICS-BASEL, 2022, 11 (05):
  • [29] In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates
    Shuford, Jennifer A.
    Piper, Kerryl E.
    Steckelberg, James M.
    Patel, Robin
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 57 (03) : 277 - 281
  • [30] In vitro combination of antifungal drugs with tacrolimus (FK506) holds promise against clinical Candida species, including Candida auris
    Khodavaisy, Sadegh
    Gharehbolagh, Sanaz Aghaei
    Abdorahimi, Mahsa
    Rezaie, Sara
    Ahmadikia, Kazem
    Badali, Hamid
    Meis, Jacques F.
    Mahmoudi, Shahram
    MEDICAL MYCOLOGY, 2023, 61 (07)